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A Prospective Randomized Trial of Intravitreal
Bevacizumab Versus Ranibizumab for the Management
of Diabetic Macular Edema
ANTONIO BRUNNO NEPOMUCENO, ERIKA TAKAKI, FELIPE PIACENTINI PAES DE ALMEIDA,
RENATO PERONI, JOSE´ AUGUSTO CARDILLO, RUBENS CAMARGO SIQUEIRA, INGRID URSULA SCOTT,
ANDRE´ MESSIAS, AND RODRIGO JORGE PURPOSE: To compare visual acuity and spectral-
domain optical coherence tomography (SDOCT)
outcomes associated with intravitreal (IV) bevacizumab
vs IV ranibizumab for the management of diabetic
macular edema (DME).
 DESIGN: Prospective randomized trial.
 METHODS: Forty-eight patients (63 eyes) with center-
involved DME were randomly assigned to receive
1.5 mg (0.06 cc) IV bevacizumab or 0.5 mg (0.05 cc)
IV ranibizumab at baseline andmonthly if central subfield
thickness was greater than 275 mm.
 RESULTS: Forty-five patients (60 eyes) completed
48weeks of follow-up. At baseline, mean ± standard error
best-corrected visual acuity (BCVA) (logMAR)was 0.60
(20/80) ± 0.05 in the IV bevacizumab group and 0.63
(20/85) ± 0.05 in the IV ranibizumab group. A significant
improvement in mean BCVA was observed in both
groups at all study visits (P< .05); this improvement
was significantly greater in the IV ranibizumab group
compared with the IV bevacizumab group at weeks 8
(P [ .032) and 32 (P [ .042). A significant reduction
in mean central subfield thickness was observed in both
groups at all study visits compared with baseline (P <
.05), with no significant difference in the magnitude of
macular thickness reduction between groups. The mean
number of injections was significantly higher (P[ .005)
in the IV bevacizumab group (9.84) than in the IV ranibi-
zumab group (7.67).
 CONCLUSIONS: IV bevacizumab and IV ranibizumab
are associated with similar effects on central subfield
thickness in patients with DME through 1 year of
follow-up. IV ranibizumab is associated with greater
improvement in BCVA at some study visits, and
the mean number of injections is higher in the IVAccepted for publication Apr 18, 2013.
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M
ACULAR EDEMA IS THE LEADING CAUSE OF
decreased visual acuity in patients with diabetic
retinopathy.1,2 Laser photocoagulation has been
the standard-of-care treatment for diabetic macular edema
(DME) for decades, based on the Early Treatment Diabetic
Retinopathy Study (ETDRS) and other more recent clinical
trials.3–6 However, because visual acuity improvement
post laser is observed infrequently, and because of the
frequent recurrence or persistence of DME after laser
treatment, there is a need for better treatments for the
management of DME (especially for diffuse DME
involving the foveal center, since focal DME not involving
the foveal center may have a good prognosis after focal
laser treatment).3,4,6–8 Care must be taken, however,
because the terms ‘‘diffuse’’ and ‘‘focal’’ DME have not been
defined consistently in the literature; these terms have
referred to a variety of diverse parameters (clinical and
angiographic) itemized differently by various authors.7–9 In
addition, the definition of center- and non-center-involved
DMEmay vary; the Diabetic Retinopathy Clinical Research
Network (DRCRnet) has defined non-center-involved
DME as ‘‘a baseline central subfield thickness<250 microns
and a baseline photograph assessment of retinal thickness at
the center of the macula graded as none or questionable.’’7
Moreover, the parameters of a ‘‘normal’’ central subfield
threshold may vary depending on the optical coherence
tomography (OCT) machine employed.10
Among pharmacologic treatments currently available
for DME, antiangiogenic agents such as bevacizumab and
ranibizumab have been reported to be associated with
visual acuity improvement and favorable remodeling of
the macular architecture in patients with DME.11–16
Ranibizumab has been evaluated in phase III prospective
randomized clinical trials and reported to be associated
with better visual acuity outcomes compared to focal/grid
laser in patients with DME.12,13 To our knowledge and
based on a Medline search, there is no published study
comparing intravitreal (IV) bevacizumab and IV
ranibizumab for the treatment for DME. We conducted
a randomized, prospective study to compare the visual0002-9394/$36.00
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acuity and spectral-domain optical coherence tomography
(SDOCT) outcomes associated with IV bevacizumab vs IV
ranibizumab for the management of DME.METHODS
THE CURRENT STUDY IS A PROSPECTIVE RANDOMIZED CLIN-
ical trial registered at ClinicalTrials.gov (NCT01487629).
The study protocol adhered to the tenets of the Declaration
of Helsinki and was approved by the local Institutional
Review Board, Comiteˆ de E´tica em Pesquisa do Hospital
das Clı´nicas da Faculdade de Medicina de Ribeira˜o Preto,
and all participants gave written informed consent before
entering into the study. All patients evaluated in the
Retina Section of the Department of Ophthalmology,
School of Medicine of Ribeira˜o Preto of the University of
Sao Paulo with center-involved DME in at least 1 eye
between July 1, 2010 and August 31, 2011 were invited
to participate in the study.
 PATIENT ELIGIBILITY AND BASELINE EVALUATION:
Inclusion criteria. Inclusion criteria were as follows: (1)
center-involved DME, defined as a central subfield
thickness >300 mm on SDOCT, despite at least 1 session
of macular laser photocoagulation performed at least
3 months previously; (2) best-corrected ETDRS visual
acuity (BCVA) measurement between 0.3 logMAR
(Snellen equivalent: 20/40) and 1.6 logMAR (Snellen
equivalent: 20/800); (3) signed informed consent.
Exclusion criteria. Exclusion criteria were: (1) vitreo-
macular traction on SDOCT; (2) proliferative diabetic
retinopathy needing panretinal photocoagulation (PRP)
or anticipated to need PRP in the next 12 months; (3)
macular capillary dropout on fluorescein angiography; (4)
history of glaucoma or ocular hypertension (defined as an
intraocular pressure higher than 22 mm Hg); (5) an ocular
condition (other than diabetes) that, in the opinion of the
investigator, might affect macular edema or alter visual
acuity during the course of the study (eg, retinal vein occlu-
sion, uveitis or other ocular inflammatory disease, neovas-
cular glaucoma, etc); (6) systemic corticosteroid therapy;
(7) any condition that, in the opinion of the investigator,
might preclude follow-up throughout the study period.
Each patient received a detailed ophthalmologic exami-
nation including measurement of BCVA according to the
standardized ETDRS refraction protocol using a retroillu-
minated Lighthouse for the Blind distance visual acuity
test chart (using modified ETDRS charts 1, 2, and R; Preci-
sion Vision, IL), as well as applanation tonometry, undi-
lated and dilated slit-lamp biomicroscopic examination,
indirect fundus examination, and fluorescein angiography
using high-resolution angiography (HRA; Heidelberg
Engineering, Heidelberg, Germany).VOL. 156, NO. 3 BEVACIZUMAB VERSUS RANIBIZUMABFourier-domain OCT evaluation (Spectralis Eyetracker
Tomographer, HRA-OCT; Heidelberg Engineering) was
performed in all patients, and retinal thickness measure-
ments were acquired using a standard 203 15-degree raster
scan protocol consisting of 19 horizontal sections (each
computed out of 25 frames) with a distance of 240 mm
between each horizontal scan, covering a square of 20 3
15 degrees on the retina and centered on the foveal region.
Follow-up mode was used to reduce test-retest variability.
In order to optimize the accuracy of OCT data, automatic
delineation of the inner and outer boundaries of the neuro-
sensory retina generated byOCT built-in software was veri-
fied for each of the scans. Central subfield thickness values
were calculated automatically as the average thickness of
a central macular region 1000 mm in diameter centered
on the patient’s foveola by built-in Heidelberg software
using retinal map analysis.
 INTRAVITREAL INJECTION: If both eyes were eligible for
treatment and the patient agreed to treat both eyes with
anti-VEGF therapy, 1 eye received the randomized treat-
ment according to a computer-generated sequence and
the contralateral eye received the other anti-VEGF agent
on the next day; thus, if an eye was randomized to the rani-
bizumab group, the contralateral eye was allocated to the
bevacizumab group. All injections were performed using
topical proparacaine drops under sterile conditions (eyelid
speculum and povidone-iodine). Before the injection was
performed, the eyelids were scrubbed with 10% povidone-
iodine, and 5% povidone-iodine drops were applied to
the conjunctiva. The time between application of 5%
povidone-iodine solution to the conjunctiva and adminis-
tration of the intravitreal injection was 2 minutes.
Povidone-iodine was applied to the conjunctiva directly
over the intended injection site.17–20 Care was taken in
all cases to insure that the needle did not touch the lids
or lashes. Bevacizumab (1.5 mg/0.06 cc; F. Hoffmann- La
Roche Ltd., Basel, Switzerland) or ranibizumab (0.5 mg/
0.05 cc; Novartis Pharma Stein AG, Stein, Switzerland)
was injected into the vitreous cavity using a 29-gauge 0.5-
inch needle inserted through the inferotemporal pars plana
3.0-3.5 mm posterior to the limbus.21 After the injection,
central retinal artery perfusion was confirmed with indirect
ophthalmoscopy. Patients were instructed to instill 1 drop
of 0.3% ciprofloxacin into the injected eye 4 times daily
for 1 week after the procedure.
 RETREATMENTPROTOCOL: Retreatment with the origi-
nally assigned treatment was performed monthly if central
subfield thickness was greater than 275 mm.
 RESCUE THERAPY: If, after 3 consecutive injections,
there was not a reduction in central subfield thickness of
at least 10% or an increase in BCVA of at least 5 letters
compared with baseline, the patient could, at the discretion
of the treating ophthalmologist, receive focal/grid laser503FOR DIABETIC MACULAR EDEMA
photocoagulation or continue to receive the same intravi-
treal medication for an additional 3 consecutive visits.
 FOLLOW-UP EXAMINATIONS AND OUTCOME
MEASURES: Patientswere scheduled for follow-up examina-
tions at monthly intervals. At these visits, patients’ BCVA
was determined after ETDRS refraction, and they under-
went complete ophthalmic examination using the same
procedures as at baseline, with the exception of fluorescein
angiography, which was performed only at the final follow-
up visit. Examiners (E.T., F.P.P.A., R.P.) were masked
regarding which treatment drug was used for each patient.
Throughout the study, a single masked, certified examiner
performed BCVA measurements prior to any other study
procedure. Patients, OCT technicians, and fundus photog-
raphers were also masked to treatment group. Outcome
measures include changes in ETDRS BCVA, changes in
central subfield thickness, and occurrence of complications.
 STATISTICAL ANALYSIS: BCVA and central subfield
thickness measured at each follow-up visit were compared
with baseline BCVA and central subfield thickness values
for within- and between-group comparisons, which were
performed using multiple analysis of variance (MANOVA)
for repeatedmeasurements. Proportions of eyes with central
subfield thickness <_275 mmwere compared using the likeli-
hood ratio x2 test. In addition, a multivariate analysis
comparing BCVA and central subfield thickness outcomes
in the IV bevacizumab group and IV ranibizumab group was
performed, taking into account number of injections, base-
line BCVA, and central subfield thickness as effects.
A statistically significant effect was defined if P< .05, and
a trend towards significance was reported if P < .1. Statis-
tical analyses were performed using JMP 10.0.0 (2010;
SAS Institute Inc, Cary, North Carolina, USA) software.
 SAMPLE SIZE: Sample size and powering were based on
a previous clinical trial on bevacizumab use for diabetic
macular edema,14 where a mean change observed in central
subfield thickness from baseline was 130 mm with a stan-
dard deviation of 122mm. Therefore, to have 80% power to
detect a difference of 50mmbetween central subfield thick-
ness change found in both groups, the sample size required
in each group was 25 eyes. Thirty eyes per treatment group
were required if one assumed a 10% dropout rate. With this
sample size, there is a 20% chance for a failure to detect
a true mean difference of at least 50 mm between the treat-
ment groups (type I error), or for an incorrect conclusion
that a difference of at least 50 mm exists between the treat-
ment groups (type II error).
RESULTS
A TOTAL OF 48 PATIENTS WITH CENTER-INVOLVED DME IN
at least 1 eye were identified during the study period.504 AMERICAN JOURNAL OFForty-five patients (60 eyes; IV ranibizumab: 28 eyes, IV
bevacizumab: 32 eyes) were included in the outcomes anal-
yses; all patients were included in the safety analyses. The 3
patients excluded from the outcomes analyses consisted of
1 patient in the IV ranibizumab group who developed
Staphylococcus aureus endophthalmitis after the first injec-
tion (this patient chose to exit the study and he did not
complete any further study visits); 1 patient in the IV beva-
cizumab group who developed advanced posterior subcap-
sular cataract, which precluded adequate SDOCT images,
after the ninth follow-up visit; and 1 patient from the IV
bevacizumab group who missed 3 consecutive follow-up
visits.
Another patient in the IV ranibizumab group developed
Streptococcus mitis endophthalmitis after the 44-week study
visit, but he completed all study visits and his data were
included in the analysis. One patient in the IV bevacizu-
mab group developed transient inferior vitreous hemor-
rhage attributable to acute posterior vitreous detachment
at week 36 and was also maintained in the analysis.
Fifteen patients with bilateral DME received IV ranibi-
zumab in 1 eye and IV bevacizumab in the other eye, and
30 patients received unilateral treatment. Forty percent
of eyes (24/60) had proliferative diabetic retinopathy
treated with PRP at least 6 months before the initial eval-
uation. Mean duration of DME estimated by the patients’
reported duration of decreased vision was 37.3 months
and 38.1 months in the IV bevacizumab and IV ranibizu-
mab groups, respectively. The time interval between the
last anti-VEGF or steroid treatment and study enrollment
was at least 6 months. In the bevacizumab group, the
number of eyes that had received IV triamcinolone, beva-
cizumab, or ranibizumab prior to entering the current study
was 1, 3, and 2 eyes, respectively; in the ranibizumab group,
the number of eyes that had received IV triamcinolone,
bevacizumab, or ranibizumab prior to entering the current
study was 2, 3, and 2 eyes, respectively. Baseline character-
istics are summarized in Table 1.
 OUTCOME MEASURES: Best-corrected visual acuity. At
baseline, mean BCVA (logMAR) 6 standard error (SE)
was 0.60 (Snellen equivalent: 20/80) 6 0.05 and 0.63
(Snellen equivalent: 20/85)6 0.06 in the IV bevacizumab
and IV ranibizumab groups, respectively (P ¼ .680). Intra-
group significant improvement in mean BCVA compared
with baseline was observed at all study follow-up visits (P
< .05). Maximum mean BCVA improvement occurred at
weeks 44 and 48 (0.23 6 0.02 logMAR: w2.5 ETDRS
lines) in the IV bevacizumab group and at week 48
(0.29 6 0.04 logMAR: w3 ETDRS lines) in the IV
ranibizumab group. There was a significantly greater
mean improvement in BCVA in the IV ranibizumab
group compared with the IV bevacizumab group at weeks
8 (P ¼ .0318) and 32 (P ¼ .0415), with a trend towards
significance at weeks 28, 36, and 40 (P < .10) (Table 2,
and Figure 1, Top).SEPTEMBER 2013OPHTHALMOLOGY
TABLE 1. Baseline Characteristics of Patients Treated With Intravitreal Bevacizumab Versus Ranibizumab for the Management of
Diabetic Macular Edema
Baseline Characteristics Bevacizumab Group Ranibizumab Group
Age (years) (mean þ SE) 63.8 6 8.8 63.7 6 9.0
Sex (male/female) 13/19 14/14
Race (black/Hispanic/white) 4/4/24 6/4/18
Duration of diabetes (years) (mean þ SD) 16.2 6 8.0 15.9 6 8.0
Phakic 23 21
Pseudophakic 9 7
Treatment regimen: no insulin 13 13
Treatment regimen: insulin 19 15
HbA1c (mean 6 SD) 8.6 6 1.3 8.7 6 2.0
Systolic blood pressure (mm Hg) (mean 6 SD) 139.3 6 16.5 143.1 6 20.1
Diastolic blood pressure (mm Hg) (mean 6 SD) 78.6 6 11.2 80.5 6 11.9
Grid photocoagulation sessions (n) (mean 6 SD) 1.41 6 0.87 1.51 6 0.78
Moderate or severe nonproliferative diabetic retinopathy 19 17
Diabetic retinopathy treated with PRP 13 11
HbA1c ¼ glycosylated hemoglobin A1c; PRP ¼ panretinal photocoagulation.
TABLE 2. Mean and Standard Error for Best-Corrected Visual Acuity and Central Subfield Thickness in the Intravitreal Bevacizumab
and Intravitreal Ranibizumab Groups for the Management of Diabetic Macular Edema, During 48-Week Follow-up Period
Week
Best-Corrected Visual Acuity (logMAR) Central Subfield Thickness (mm)
IV Bevacizumab IV Ranibizumab Pa IV Bevacizumab IV Ranibizumab P
0 0.60 6 0.05 0.63 6 0.06 451.7 6 22.3 421.9 6 23.1
4 0.48 6 0.06 0.53 6 0.06 .6613 385.3 6 20.9 328.9 6 18.0 .2615
8 0.48 6 0.06 0.46 6 0.06 .0318 357.2 6 17.6 313.9 6 15.2 .4407
12 0.45 6 0.05 0.46 6 0.05 .1893 347.3 6 17.5 309.3 6 18.0 .5106
16 0.42 6 0.05 0.43 6 0.06 .2481 347.6 6 17.7 316.8 6 14.5 .6035
20 0.41 6 0.05 0.42 6 0.06 .2590 343.6 6 20.5 304.0 6 17.9 .4934
24 0.41 6 0.05 0.40 6 0.05 .1457 342.8 6 18.4 300.4 6 12.4 .4584
28 0.43 6 0.06 0.40 6 0.05 .0659 352.1 6 20.1 293.9 6 13.9 .2839
32 0.41 6 0.06 0.36 6 0.04 .0415 351.1 6 19.5 295.6 6 15.5 .3091
36 0.40 6 0.06 0.36 6 0.04 .0543 344.5 6 20.6 287.7 6 14.7 .3173
40 0.39 6 0.06 0.35 6 0.04 .0635 354.0 6 21.5 291.2 6 10.4 .2315
44 0.36 6 0.05 0.34 6 0.04 .1326 339.8 6 19.5 281.2 6 14.3 .2843
48 0.36 6 0.05 0.34 6 0.04 .1886 329.7 6 19.3 280.9 6 12.6 .4865
IV ¼ intravitreal.
aDark gray background highlights P < .05; light gray background highlights P < .10.With respect to the proportion of eyes losing or gaining
>_10 or >_15 ETDRS letters, no significant difference
between IV bevacizumab and IV ranibizumab groups was
observed (P > .05).
In the IV bevacizumab group, the proportion of eyes
losing >_10 ETDRS letters was 6% at week 16 and from
weeks 28-40, and 3% at weeks 12, 20, and 24. The propor-
tion of eyes in the IV bevacizumab group that lost >_15
letters was 3% at weeks 32 and 36. In the IV ranibizumab
group, a loss of >_10 ETDRS letters was not observed at
any follow-up visit. A gain of >_10 ETDRS letters was
observed in 45% and 44% of eyes in the IV bevacizumabVOL. 156, NO. 3 BEVACIZUMAB VERSUS RANIBIZUMABand IV ranibizumab groups, respectively, at week 16, and
in 61% and 68% in the 2 groups, respectively, at week
48. A gain of >_15 letters was observed in 15% and 16%
of eyes in the IV bevacizumab and IV ranibizumab groups,
respectively, at week 16, and in 39% and 48% in the 2
groups, respectively, at week 48 (Figure 1, Bottom).
Central subfield thickness. Atbaseline,mean6SEcentral
subfield thickness was 451 6 22 mm and 421 6 23 mm at
baseline in the IV bevacizumab and IV ranibizumab groups,
respectively (P ¼ .4062) (Figure 2, Top). Intragroup
significant reduction in central subfield thickness505FOR DIABETIC MACULAR EDEMA
FIGURE 1. Best-corrected visual acuity in intravitreal (IV)
bevacizumab vs ranibizumab for the management of diabetic
macular edema. (Top) Best-corrected visual acuity (BCVA)
plotted against follow-up visit for IV bevacizumab vs ranibizu-
mab for the management of diabetic macular edema. Points
represent the mean BCVA change in logMAR and error bars
the 95% confidence limits at each study follow-up visit
compared with baseline. The magnitude of BCVA improvement
was significantly higher in the IV ranibizumab group compared
with the IV bevacizumab group at weeks 8 (P [ .03) and 32
(P [ .04), with a trend towards significance at weeks 28
(P[ .06), 36 (P[ .05), and 40 (P[ .06). (Bottom) Propor-
tion of eyes treated with IV bevacizumab (black circles) and
ranibizumab (open circles) gaining ‡10 or ‡15 ETDRS letters:
No statistically significant difference was observed between
groups for gain of ‡10 or ‡15 letters at any study visit.
FIGURE 2. Intravitreal (IV) bevacizumab vs ranibizumab for
themanagement of diabetic macular edema. (Top) Circles repre-
sent the mean and error bars the 95% confidence limits for
central subfield thickness at each study visit. The mean central
subfield thickness in the IV ranibizumab group was lower than
the central subfield thickness in the IV bevacizumab group at
all follow-up visits, although the difference between the 2
groups was not statistically significant. (Bottom) Mean change
in central subfield thickness (mm) ± 95% confidence limits at
each study follow-up visit compared with baseline. There was
no significant difference between the IV bevacizumab group
and IV ranibizumab group in the magnitude of central subfield
thickness change at any of the study follow-up visits.compared with baseline was observed at all study follow-up
visits (P < .05). Maximum mean central subfield thickness
reduction occurred at week 44 (136 6 23 mm) in the IV
ranibizumab group and at week 48 (126 6 25 mm) in
the IV bevacizumab group (Table 2, and Figure 2,
Bottom). There was no difference in mean central subfield
thickness reduction between the IV bevacizumab and IV
ranibizumab groups at any of the study follow-up visits.
However, there was a significantly higher proportion of
eyes with a central subfield thickness <_275 mm in the IV
ranibizumab group compared with the IV bevacizumab
group at weeks 4 (P ¼ .0029; likelihood ratio), 28 (P ¼
.0077), 36 (P ¼ .0028), and 44 (P ¼ .0292) (Figure 3).
Number of intravitreal injections. The mean (6 standard
error of the mean; SEM) number of injections in the IV506 AMERICAN JOURNAL OFbevacizumab groupwas 9.846 0.55, whichwas significantly
(P ¼ .005; Wilcoxon) higher than the mean (6 SEM)
number of injections in the IV ranibizumab group (7.67 6
0.60 injections). In the IV bevacizumab group, 16 eyes
received 12 injections, while only 4 eyes from the IV rani-
bizumab group were treated with 12 injections (Figure 4).
Rescue therapy. Two eyes from 2 different patients
received rescue laser therapy: 1 from the IV ranibizumab
group at week 32 and the other from the IV bevacizumab
group at week 36. An additional 8 patients (8 eyes) from
the IV bevacizumab group and 3 patients (3 eyes) from
the IV ranibizumab group met the criteria for rescue
therapy during the study period and these patients elected
to be treated with 3 additional consecutive injections of
their originally assigned treatment. The number of eyes
that met the criteria for rescue therapy during the study
period was significantly higher in the IV bevacizumab
group (n ¼ 9) compared with the IV ranibizumab group
(n ¼ 4) (P ¼ .042; paired t test).SEPTEMBER 2013OPHTHALMOLOGY
FIGURE 3. Proportion of eyes with diabetic macular edema treated with intravitreal (IV) bevacizumab (black bars) and ranibizumab
(white bars) with central subfield thickness £275 mm. The proportion was significantly higher in the IV bevacizumab group at weeks
4 (P[ .029), 28 (P[ .007), 36 (P[ .0028), and 44 (P[ .029) (likelihood ratio) when compared with the IV ranibizumab group.
FIGURE 4. Mean diamond plots summarizing the distribution
of number of intravitreal (IV) injections of bevacizumab and
ranibizumab for management of diabetic macular edema after
48 weeks. The center horizontal line represents the mean, and
the superior and inferior lines represent the 95% and 5% confi-
dence limits, respectively. The mean number of injections
(± standard error) was 9.84 ± 0.55 and 7.67 ± 0.60 in the IV
bevacizumab group and IV ranibizumab group, respectively
(P[ .005; Wilcoxon).Multivariate analysis. A multivariate analysis comparing
BCVA and central subfield thickness outcomes between
the IV bevacizumab and IV ranibizumab groups, taking
into account number of injections, baseline BCVA, and
central subfield thickness, demonstrated a statistically
significant influence of baseline BCVA on follow-up
BCVA (P < .001) but no other significant differences
between groups (P ¼ .051) across follow-up time (P ¼
.490) regarding these 2 outcomes.VOL. 156, NO. 3 BEVACIZUMAB VERSUS RANIBIZUMABAdverse events. There was no significant change in mean
intraocular pressure compared with baseline at any of the
study follow-up visits in either group (P < .05). In the IV
bevacizumab group, 1 patient experienced clinically
significant cataract progression that prevented a clear
view of the fundus after his ninth visit and another
patient developed transient vitreous hemorrhage after an
acute posterior vitreous detachment.
There were 2 patients who developed endophthalmitis in
the IV ranibizumab group (both patients were treated
unilaterally) and1patient, also in the IV ranibizumabgroup,
who experienced increased blood pressure, controlled with
oral antihypertensive agents. Additionally, 1 patient devel-
oped transient worsening of renal function. This patient,
who had the right eye treated with ranibizumab and the
left eye treated with bevacizumab, had a serum creatinine
level of 2.0 mg/dL at baseline and, during the study, his
creatinine level increased to 2.9 mg/dL; at the last study
visit, his creatinine level had returned to 2.0 mg/dL. No
patient experiencedmyocardial infarction, stroke, or gastro-
intestinal bleeding throughout the study period.DISCUSSION
IN THE PRESENT STUDY, BOTH GROUPS ACHIEVED SIGNIFI-
cant improvement in BCVA compared with baseline at
all study visits (P < .05). At week 48, there was a mean
BCVA improvement of 0.23 logMAR (w11 letters)
and 0.27 logMAR (w13 letters) in the IV bevacizumab
and IV ranibizumab groups, respectively. Similarly,
DRCR.net12 reported a mean BCVA improvement of 8.2
letters in patients with DME treated with IV ranibizumab
plus prompt laser and 8.4 letters in patients treated with
IV ranibizumab plus deferred laser after 1 year of follow-
up. More recently, the RISE and RIDE13 studies also
showed significant improvements in BCVA associated
with IV ranibizumab treatment for DME. In the RISE507FOR DIABETIC MACULAR EDEMA
study, the IV ranibizumab 0.5 mg group demonstrated
a mean improvement of 12 letters in BCVA at 1 year,
and in the RIDE study, the IV ranibizumab 0.5 mg group
demonstrated a mean improvement of 11 letters in
BCVA at 1 year. Similarly, the BOLT14 study reported
a significant mean improvement in BCVA after anti-
VEGF treatment for DME; eyes treated with IV bevacizu-
mab gained a mean of 5.6 letters at 1 year of follow-up.
Although both groups achieved a significant improve-
ment in mean BCVA, IV ranibizumab eyes demonstrated
significantly greater BCVA gains when compared with IV
bevacizumab eyes at weeks 8 and 32 and a trend toward
significance at weeks 28, 36, and 40. This difference
between the groups at these time points during follow-
up may be attributable to lower central subfield thickness
values in the IV ranibizumab group compared with the IV
bevacizumab group at these periods (Figure 2, Top) and,
consequently, a significantly higher proportion of patients
with a central subfield thickness <_275 mm in the IV rani-
bizumab group (Figure 3). Correspondingly, the propor-
tion of IV bevacizumab eyes that met the criterion for
rescue therapy was significantly higher in the IV bevacizu-
mab group compared with the IV ranibizumab group.
Despite significant differences between groups in BCVA
at weeks 8 and 32, it is important to note that because
the sample size calculation for this study was based on
the difference between treatment groups with respect to
central subfield thickness, conclusions regarding BCVA
are limited: the lack of a significant difference between
treatment groups with respect to BCVA at some study
visits does not necessarily indicate that both anti-VEGF
treatments have an equivalent effect on BCVA. In other
words, a significant difference between groups may have
been detected at other study visits if the study had been
conducted with a sample size based on differences in
BCVA rather than on differences in central subfield
thickness.
Significant improvements in central subfield thickness
compared with baseline were observed in both the IV beva-
cizumab and IV ranibizumab groups. At week 48, both
groups demonstrated a mean central subfield thickness
reduction compared with baseline of 120 mm. Similarly,
the DRCR.net12 reported a mean improvement in central
subfield thickness of 131 mm and 137 mm in patients
with DME treated with IV ranibizumab plus prompt or
deferred laser, respectively, after 1-year follow-up. More
recently, the RISE and RIDE13 studies reported a mean
central subfield thickness reduction at 1 year of 250 mm
in patients with DME treated with IV ranibizumab. The
greater absolute value of central subfield thickness reduc-
tion observed in the RISE and RIDE studies may be related
to higher baseline central foveal thickness values and/or
more constant VEGF blockage with monthly treatment
compared to the DRCR.net study,12 in which the mean
number of injections was 8 per year, and the present study,
in which the mean number of injections was 7.67 per year.508 AMERICAN JOURNAL OFIt is also important to note that the multivariate analysis in
the current study did not demonstrate any influence of
baseline central subfield thickness on the number of injec-
tions in either study group. Treatment with IV bevacizu-
mab has also been reported to be associated with
favorable anatomic effects in patients with DME; the
BOLT14 study reported a mean central subfield thickness
reduction at 1 year of 130 mm, which is very similar to
the 120 mm reduction observed in the IV bevacizumab
group of the present study.
Despite no significant difference in the magnitude of
absolute central subfield thickness reduction between the
IV bevacizumab and IV ranibizumab groups, there was
a higher proportion of eyes with a central subfield thickness
<_275 mm in the IV ranibizumab group compared with the
IV bevacizumab group at all study follow-up visits; at weeks
4, 28, 36, and 44, this difference was statistically significant.
Since reinjections were guided by this anatomic parameter
(central subfield thickness), IV bevacizumab eyes were
treated with a significantly higher mean number of intravi-
treal injections (9.89) compared with IV ranibizumab eyes
(7.67), yet achieved similar central subfield thickness
and BCVA outcomes compared with IV ranibizumab eyes
at week 48. It is also important to point out a possible cross-
over effect of bevacizumab in the contralateral eyes of the
15 patients treated bilaterally, which may have positively
influenced central subfield reduction in ranibizumab-
treated contralateral eyes. However, there also may have
been a crossover effect of ranibizumab. This potential cross-
over effect represents a limitation for studies that permit
bilateral anti-VEGF treatment.
The reinjection criterion (a central subfield thickness
>275 mm) was based on data from patients with chronic
DME that responded with favorable macular remodeling
and were considered to demonstrate ‘‘no fluid’’ on OCT
after intravitreal anti-VEGF treatment (L. Barroso et al,
unpublished data, November 2012). It has been reported
that for patients with chronic DME, a lower central subfield
thickness threshold value should be established in compar-
ison to normal population values,22,23 probably because of
some degree of central retinal atrophy related to previous
laser or mild to moderate ischemia.24 Consistent with the
latter report, in the present study no patients with ‘‘no fluid’’
on OCT at week 48 had a central subfield thickness
>_275 mm. In addition, in the present study, among the 42
eyes that had any degree of concave foveal contour at
week 48 despite some fluid on OCT, only 5 (12%) had
a central subfield thickness >275 mm (L. Barroso et al,
unpublished data, November 2012).
No difference in intraocular pressure between the 2
groups was observed throughout the study, and no signifi-
cant change in intraocular pressure was observed at any
study visit compared with baseline in either group. The
results of the current study are consistent with data from
other studies that reported no apparent association
between intravitreal anti-VEGF injection and increase inSEPTEMBER 2013OPHTHALMOLOGY
intraocular pressure,25,26 and are in contrast to some studies
that have suggested such an association.27,28 There were 2
cases of endophthalmitis in the IV ranibizumab group
among a total of 553 injections administered in the
study. The DRCR.net25 reported 3 cases of endophthalmi-
tis out of a total of 3973 injections (0.08%) in ranibizumab
arms. The RISE and RIDE studies,13 taken together,
reported a total of 4 endophthalmitis cases among a total
of 10 584 injections administered. In the current study,
all injections were performed in an ambulatory operating
room, following recommended aseptic practices.17–20 The
relatively high endophthalmitis rate in our study may be
related to patient-related characteristics, such as poor
socioeconomic status and hygiene habits.17 Finally, admin-
istering anti-VEGF to both eyes may increase the risk of
systemic complications; in fact, 1 of these patients had
transient increase in creatinine levels during the study.VOL. 156, NO. 3 BEVACIZUMAB VERSUS RANIBIZUMABIn sum, in the current study, IV bevacizumab and IV
ranibizumab were associated with improvement in mean
BCVA and mean central subfield thickness in patients
with center-involved DME at 48 weeks of follow-up
when compared with baseline. Eyes in the IV bevacizumab
group received a significantly higher number of injections
than eyes in the IV ranibizumab group. During the study,
eyes in the IV ranibizumab group experienced a faster
recovery of BCVA compared with eyes in the IV bevacizu-
mab group, which may be explained by the higher propor-
tion of eyes in the IV ranibizumab group with a central
subfield thickness <275 mm at intermediate-term study
follow-up visits. To our knowledge and based on a Medline
search, this is the first report comparing IV bevacizumab
and IV ranibizumab for the treatment of DME. The current
study is limited by a small sample size; larger prospective
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